trending Market Intelligence /marketintelligence/en/news-insights/trending/JQfhtWWwYN1LjqrNICLjJA2 content esgSubNav
In This List

Immunomedics secures patent for investigational cancer treatment

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Immunomedics secures patent for investigational cancer treatment

Immunomedics Inc. secured patent coverage for its IMMU-140 cancer treatment in the U.S.

The protection will last until July 2033 and will cover the use of IMMU-140 in multiple cancer types, including melanoma, kidney or liver.

IMMU-140 is an investigational drug that is currently under development.